Clinical Considerations for Cannabis Use

Danielle Backus PharmD BCGP
John Begert PharmD BCACP
Kaitlyn Pinner PharmD Candidate 2019
Learning Objectives

- Apply literature to determine potential benefits of cannabis products for future patients
- Identify clinically-relevant drug-drug interactions with THC and CBD, classifying them as pharmacodynamic or pharmacokinetic in nature
Baby Boomers on the Rise

- Currently 75.4 million baby boomers (born 1946-1964)
- By 2050, those ≥65 will be estimated at 83.7 million
- Grew up in a dynamic and changing world
  - Vietnam war
  - Civil rights movement
  - Sexual revolution
  - Women’s liberation
  - Drugs

Potter SB. https://insight.factset.com/millennials-outnumber-baby-boomers-but-dont-count-them-out
Perceptions are Changing

Support for Legalizing Marijuana Continues to Edge Up
Do you think the use of marijuana should be made legal, or not?

% Yes, legal

12 16 28 25 23 25 31 36 44 50 58 58 64 66

GALLUP

Adapted from Mccarthy J. Two in one Americans now support legalizing marijuana. Available at https://news.gallup.com/poll/243908/two-three-americans-support-legalizing-marijuana.aspx?g_source=link_NEWSV9&g_medium=TOPIC&g_campaign=item&_g_content=Two%2520in%2520Three%2520Americans%2520Now%2520Support%2520Legalizing%2520Marijuana
Prevalence estimates for self-reported past-year cannabis use for adults 50 years and older, US 2003-2016

<table>
<thead>
<tr>
<th>Prevalence of cannabis use</th>
<th>2006/2007 (n=11,181)</th>
<th>2012/2013 (n=12,696)</th>
<th>% absolute change from 06/07 to 12/13</th>
<th>% relative change from 06/07 to 12/13</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalence of cannabis use</td>
<td>2.8</td>
<td>4.8</td>
<td>+2.0</td>
<td>+71.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age group 50-64</td>
<td>4.5</td>
<td>7.1</td>
<td>+2.6</td>
<td>+57.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age group 65+</td>
<td>0.4</td>
<td>1.4</td>
<td>+1.0</td>
<td>+250.0</td>
<td>0.002</td>
</tr>
<tr>
<td>Gender Male</td>
<td>4.4</td>
<td>6.8</td>
<td>+2.4</td>
<td>+54.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Gender Female</td>
<td>1.5</td>
<td>3.0</td>
<td>+1.5</td>
<td>+100.00</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Adapted from Han BH. Addiction. 2017 March;112(3):516-525. doi:10.1111/add.13670.
Figure 12. Current marijuana use among Oregon adults by age, 2014 and 2015

Note: “Current” marijuana use is defined as any marijuana use in the past 30 days.

Why and what does this mean?

What can be the effects?

- Improved quality of life?
- Increased risk for falls?
- Reduced prescription medication use?
- Illicit drug use?
- Cost savings?
- Dependency/addiction?

Figure 23. Oregon medical marijuana patient conditions, 2015

Data source: Oregon Medical Marijuana Program (OMMP) (October 2015 Statistical Snapshot).
Are marijuana and cannabis the same thing?

Cannabis… Marijuana… THC… CBD…
The Human Endocannabinoid System

CBD, CBN, and THC fit like a lock and key into existing human receptors. These receptors are part of the endocannabinoid system which impact physiological processes affecting pain modulation, memory, and appetite plus anti-inflammatory effects and other immune system responses. The endocannabinoid system comprises two types of receptors, CB1 and CB2, which serve distinct functions in human health and well-being.

CB1 receptors are primarily found in the brain and central nervous system, and to a lesser extent in other tissues.

CBD does not directly “fit” CB1 or CB2 receptors but has powerful indirect effects still being studied.

CB2 receptors are mostly in the peripheral organs especially cells associated with the immune system.

https://medium.com/randys-club/supporting-your-endocannabinoid-system-5db4c35d6037
Cannabis

<table>
<thead>
<tr>
<th>CBD</th>
<th>THC</th>
</tr>
</thead>
<tbody>
<tr>
<td>No activity at CB1 or CB2 receptors</td>
<td>Activates CB1 &amp; CB2 receptors</td>
</tr>
</tbody>
</table>


https://kalytera.co/cbd/
https://en.wikipedia.org/wiki/Tetrahydrocannabinol
<table>
<thead>
<tr>
<th>Effects</th>
<th>THC</th>
<th>CBD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticonvulsant</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>Muscle Relaxation</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Psychoactive</td>
<td>++</td>
<td>--</td>
</tr>
<tr>
<td>Anxiolytic</td>
<td>--</td>
<td>++</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>+</td>
<td>--</td>
</tr>
<tr>
<td>Appetite Stimulant</td>
<td>+</td>
<td>--</td>
</tr>
<tr>
<td>Antioxidant</td>
<td>+</td>
<td>++</td>
</tr>
</tbody>
</table>

Rx Products

- Dronabinol (Marinol) oral solution, capsules
  - Pure THC; CIII

- Nabilone
  - Synthetic analog of THC; CII

- Cannabidiol (Epidiolex) oral solution
  - Pure CBD; CV
Epidiolex (Cannabidiol)

- Doses range from 2.5-10 mg/kg BID for seizures
  - Example: 75 kg male: 188 – 750 mg twice daily
  - Higher doses = higher efficacy, but more adverse effects
  - Recent FDA approval, so little-to-no data for safety or efficacy in older adults
Non-Rx CBD Products

https://keytocannabis.com/blogs/cannabis/which-kind-of-cbd-will-work-for-me


https://madebyhemp.com/product/therapeutic-cbd-chocolate/
What disease states are cannabis, THC, or CBD used for?
Parkinson’s Disease

- Cannabinoids are neuroprotective hypothesis
  - Low CB1 receptors concentration in PD patients

- Majority of evidence available for levodopa-induced dyskinesia in Parkinson's disease
  - Three RCTs, 48 patients
  - Oral cannabis extract had no effect on dyskinesia
  - Some discrepancy in QOL outcomes

- Evidence for benefits are mostly anecdotal for improvement of pain, anxiety and sleep

More SV. Mol Neurodegener. 2015; 10: 17
Koeppel BS. Neurology. 2014 Apr 29;82(17):1556-63
Alzheimer’s Dementia

- Pre-clinical research found THC to lower beta-amyloid levels
- 4 studies, 90 participants, unclear risk of bias
  - 2.5 mg dronabinol reduced disturbed behavior in 12 patients
  - THC capsule 0.75 – 4.5 mg/day, no effect seen
- How does cannabis affect the brain damage associated with dementia?
  - What about the anticholinergic effects of THC?

Lim K. *Clinical Psychopharmacology and Neuroscience* 2017;15(4):301-312
Cannabis and Brain Development

- Greater decline in IQ (~6 points vs. never users) connected to persistent and younger age of use
  - Adult onset users did not experience a significant decline
  - Greatest impairment in executive functioning and processing speeds

- Relationship between early and heavy cannabis use and impairments in...
  - White matter integrity
  - Smaller whole brain and cortical grey matter volumes
  - Cognitive function
  - Increased risk of psychopathology

- Difficult to account of confounders in studies
Cannabis and Psychosis

- Insufficient evidence to support or refute use for schizophrenia and psychosis
  - Mixed evidence for impact on positive symptoms
  - Does not worsen negative symptoms
  - Potential improvement in cognitive function

- Perceived benefits outweigh risks for patients with psychosis
  - Improved sociability
  - Reduced anxiety
  - Improvement in medication side-effects

- Multiple studies have identified a correlation with cannabis use and development psychosis
The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study

Marta Di Forti, Diego Quattrone, Tom P Freeman, Giada Tripoli, Charlotte Gayer-Anderson, Harriet Quigley, Victoria Rodriguez, Hannah E Jongsm, Laura Ferraro, Caterina La Cascia, Daniele La Barbera, Ilaria Tarricone, Domenico Berardi, Andrei Szöke, Celso Arango, Andrea Tortelli, Eva Velthorst, Miguel Bernardo, Cristina Marta Del-Ben, Paulo Rossi Menezes, Jean-Paul Selten, Peter B Jones, James B Kirkbride, Bart PF Rutten, Lieuwe de Haan, Pak C Sham, Jim van Os, Cathryn M Lewis, Michael Lynskey, Craig Morgan, Robin M Murray, and the EU-GEI WP2 Group*

Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review

Theresa H M Moore, Stanley Zammit, Anne Lingford-Hughes, Thomas R E Barnes, Peter B Jones, Margaret Burke, Glyn Lewis

Dose response effect
- Greater risk with frequency of use
- Higher potency
- Younger age
In 2014, 20.2 million people had substance use disorder, 7.9 million also had a mental health disorder.
Cannabis and Substance abuse

Gateway image: https://www.recoveryfirst.org/blog/is-marijuana-a-gateway-drug/
Exit image: https://www.uline.com/Product/Detail/S-9959P/Warehouse-Signs/Exit-Sign-Plastic
Cannabis as an “Exit Drug”

- Harm reducing role?
  - Patient reported reductions in alcohol, illicit drug use and prescription medications with cannabis and return without
  - Higher rates of substitution seen with patients <40 yo, opportunity for education?
  - Binge drinking and fatal alcohol accidents reduced in states following approval of medical marijuana
  - Card carrying users demonstrated less risky behavior with alcohol, tobacco and other substances than non-card holders

Anderson DM. J Law Econ 56: 333–369
States Move to Substitute Opioids With Medical Marijuana to Quell Epidemic

Rebecca Voelker, MSJ

Article Information


New York and Illinois allow substitution of opioid prescription for marijuana with approved condition

• In light of evidence demonstrating almost 25% reduction in annual opioid overdose mortality in states with approved medical marijuana
• Following approved programs opioid prescriptions decreased
  • Medicare Part D: 2.11 mill. daily doses per year
  • Medicaid: 5.88% (medical), 6.38% (recreational)
Oregon leads U.S. in seniors hospitalized for opioids

Updated Jul 7, 2017; Posted Jul 7, 2017

Oregon DOJ says opioid manufacturer targets senior citizens, lied to sell drugs in state

Posted Sep 13, 2018

2015 state rates of opioid-related hospital stays per 100,000 people age 65 and older

The median national rate for 2015 is based on data from 23 states. The remaining states and Washington, D.C., did not provide data.

Terry L. https://www.oregonlive.com/health/2017/07/oregon_has_top_rate_in_us_of_s.html
What risks come with THC and CBD use?
In 2017, estimated 670,000 people living in rural Oregon

43% of those 65+ are living in rural areas

Evidence suggests access to cannabis and other substances is similar to urban areas
Considerations

- Remote locations
  - Access to emergency medical care
    - Higher rates of ED visits among users 50+ compared to none users

- Aggravation of comorbid conditions
  - Neurologic disorders
  - Discontinuation of medications
  - Cardiovascular concerns?
    - 20-100% increase in HR, case reports of MI associated with cannabis use

- What is the potency?

THC potencies have increased over past 20-30 years, up to 30% THC in some varieties

THC is on the rise

CBD is in decline
Pharmacokinetic Drug-Drug Interactions (DDIs)

- Pharmacokinetic DDI = alters the absorption, distribution, metabolism, or elimination of another drug

- CBD: Inhibits CYP3A4, CYP2C19, and CYP2D6
  - Decreases concentration of clopidogrel, decreases efficacy of stroke prevention
  - Increases concentration of citalopram, increases risk of QT prolongation
  - May have clinically relevant DDI with warfarin

- THC: substrate of CYP enzymes, pharmacokinetic DDIs less likely
Pharmacodynamic Drug-Drug Interactions

- Pharmacodynamic DDIs = Drugs with similar side-effect profiles having a synergistic response

- CBD: Sedating
  - Increases fall risk

- THC: Anticholinergic, Psychoactive
  - DDI with cholinesterase inhibitors (used for dementia)
  - Could contribute to delirium?
Clinical experience with cannabis, THC, and CBD
Precautions for Patients

- FDA approval ≠ safety concerns and precautions
- Don’t just “jump back in”
  - THC potencies are much higher today than in the past
- Driving under the influence is unsafe at any age, and with any cognitive impairing substance
- Be aware of increased risk for falls
- Speak with PCP before discontinuing any prescription medications
- Marijuana
  - Inconclusive

- CBD honey
  - Ineffective?
  - Contributed to fall?

- Cannabis
  - THC tincture
  - Effective for mood?
  - Increases fall risk?

- Male in 50’s with opioid dependence

- Female in 70’s with hx of brain injury

- Male in 60’s with spinal cord injury

- Marijuana
  - Effective for spasticity?
  - Effective for mood?
Additional Discussion

- Any additional clinical experiences to share?
- Any clarifying questions or additional insights about DDIs?
- We welcome any further discussion on this topic!
Learning Objectives

- Apply literature to determine potential benefits of cannabis products for future patients
- Identify clinically-relevant drug-drug interactions with THC and CBD, classifying them as pharmacodynamic or pharmacokinetic in nature